An enantioselective synthesis of sulphonamide hydroxamic acids as matrix metalloproteinase inhibitors
Authors:
- 27 November 2001
- journal article
- research article
- Published by Elsevier in Tetrahedron Letters
- Vol. 43 (4) , 683-685
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders.Drugs & Aging, 2001
- Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer TherapyDrugs, 2000
- Matrix metalloproteinases: multifunctional contributors to tumor progressionMolecular Medicine Today, 2000
- Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: Key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592Tetrahedron Letters, 1996
- Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517)Journal of Medicinal Chemistry, 1993